March 2024
1. KILIC GUNES E, Yigit Kaya S, Yaman F, Yeniay MK, et al
   Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
   Leuk Res. 2024;140:107484.
   

   >> Share

   
   January 2024
2. TYSZKA M, Maciejewska-Markiewicz D, Styburski D, Bilinski J, et al
   Altered lipid metabolism in patients with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
   Leuk Res. 2024;137:107435.
   

   >> Share

   
   November 2023
3. KARPEN R, Sen J, Wall S, Musson S, et al
   Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants.
   Leuk Res. 2023;136:107431.
   

   >> Share

   
   
4. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
   Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
   Leuk Res. 2023;136:107429.
   

   >> Share

   
   September 2023
5. LINN SM, Novitzky-Basso I, Patriquin C, Pasic I, et al
   Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure.
   Leuk Res. 2023;134:107387.
   

   >> Share

   
   
6. LIU J, Osman AEG, Bolton K, Godley LA, et al
   Germline predisposition to clonal hematopoiesis.
   Leuk Res. 2023;132:107344.
   

   >> Share

   
   July 2023
7. AR MC, El Fakih R, Gabbassova S, Alhuraiji A, et al
   Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives.
   Leuk Res. 2023;133:107365.
   

   >> Share

   
   
8. MEHDI SJ, Ghatak K, Ling W, Johnson SK, et al
   Growth and dormancy control of myeloma cells by mesenchymal stem cells.
   Leuk Res. 2023;133:107355.
   

   >> Share

   
   
9. BRUNNER AM, Huggar D, Copher R, Zhou ZY, et al
   Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
   Leuk Res. 2023;132:107353.
   

   >> Share

   
   May 2023
10. MACKOVA J, Hainz P, Krystofova J, Roubalova K, et al
    Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Leuk Res. 2023;130:107314.
    

    >> Share

    
    March 2023
11. RIBEIRO JUNIOR HL, Goncalves PG, Moreno DA, Goes JVC, et al
    Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic neoplasm.
    Leuk Res. 2023;129:107071.
    

    >> Share

    
    
12. TERAO Y, Nakayama Y, Abo M, Otobe Y, et al
    Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2023;128:107057.
    

    >> Share

    
    December 2022
13. LEBON D, Dujardin A, Caulier A, Joris M, et al
    Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
    Leuk Res. 2022;125:107005.
    

    >> Share

    
    
14. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
    Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2022;125:107004.
    

    >> Share

    
    
15. ZHANG Y, Liu C, Zhang R, Shi Y, et al
    Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
    Leuk Res. 2022;124:106997.
    

    >> Share

    
    October 2022
16. SHAH N, Cioccio J, Rakszawski K, Zheng H, et al
    Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide.
    Leuk Res. 2022;123:106969.
    

    >> Share

    
    
17. FUJIWARA SI, Murahashi R, Nakashima H, Matsuoka S, et al
    Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
    Leuk Res. 2022;121:106951.
    

    >> Share

    
    September 2022
18. QI K, Hu X, Yu X, Cheng H, et al
    Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
    Leuk Res. 2022;120:106920.
    

    >> Share

    
    July 2022
19. VIRK H, Rathore S, Anshu A, Jamwal M, et al
    Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm.
    Leuk Res. 2022;121:106922.
    

    >> Share

    
    
20. BARKHORDAR M, Kasaeian A, Janbabai G, Mousavi SA, et al
    Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-yea
    Leuk Res. 2022;120:106918.
    

    >> Share

    
    
21. BOSTANKOLU DEGIRMENCI B, Yegin ZA, Dikyar A, Aydin Kaynar L, et al
    Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia.
    Leuk Res. 2022;118:106870.
    

    >> Share

    
    February 2022
22. KUSNE Y, Xie Z, Patnaik MM
    Clonal hematopoiesis: Molecular and clinical implications.
    Leuk Res. 2022;113:106787.
    

    >> Share

    
    November 2021
23. MINAKATA D, Fujiwara SI, Murahashi R, Nakashima H, et al
    Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.
    Leuk Res. 2021;112:106750.
    

    >> Share

    
    September 2021
24. TANG S, Lu Y, Zhang P, Chen D, et al
    Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
    Leuk Res. 2021;110:106710.
    

    >> Share

    
    
25. SAPELLI J, Filho JS, Matias Vieira GM, Moura FL, et al
    BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Leuk Res. 2021;110:106689.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share